Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Current Liabilities (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Total Current Liabilities for 10 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 7.5% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, up 7.5% year-over-year, with the annual reading at $6.2 million for FY2025, 7.5% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $6.2 million at Rein Therapeutics, up from $5.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $7.7 million in Q2 2025, with the low at $1.2 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $4.5 million, with a median of $4.5 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities tumbled 76.76% in 2023, then skyrocketed 312.45% in 2024.
  • Over 5 years, Total Current Liabilities stood at $4.5 million in 2021, then fell by 24.93% to $3.4 million in 2022, then increased by 29.58% to $4.4 million in 2023, then skyrocketed by 31.11% to $5.7 million in 2024, then increased by 7.5% to $6.2 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $6.2 million, $5.7 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.